Resumen

GONZALEZ, JC; LOUIS, C  y  SALAZAR, P. Citrato de Ranitidina Bismuto con Claritromicina y Amoxacilina vs Terapia Triple con inhibidores de la bomba de Protones: Omeprazol o Lansoprazol en el tratamiento de la infección por Helicobacter Pylori. AVFT [online]. 2001, vol.20, n.1, pp.99-104. ISSN 0798-0264.

The purpose of this study is to investigate the efficacy of 2-week triple therapy with amoxycillin, clarithromycin, and ranitidine bismuth citrate (RBC) or omeprazole or lanzoprazole in curing Helicobacter pylori (Hp) infection in patients with peptic ulcer disease. The study included 152 consecutive patients with peptic disease, in whom Hp infection was confirmed by histology, were randomly assigned to a 2-week treatment with either 400 mg bid RBC (A group) or 20 mg bid Omeprazole (B group), or 30 mg bid Lanzoprazole (C group) in combination with 500 mg bid clarithromycin and 500 mg tid amoxycillin. Eradication of Hp was successful in 50% of the patients in the A group, and 73% of the patients in the B group, and 84% of the patients in the C group. The difference was significant for a low percentage of eradication in A group (p<0,01). In C group was the fastest relief of the symptons (6 days) (p<0,05) Adverse effects were seen in 21 patient in A group, 13 patients in B group, and 19 patients in C group. The difference was not significant.We concluded that eradication of Hp was significant in 2-week treatment with CRB+Cl+Am compared with L+Cl+Am. The combination L+Cl+Am were more effective in relief of the symptons than CRB+Cl+Am.

Palabras clave : Helicobacter pylori; Triple therapy; Ranitidine bismuth citrate; Lanzoprazole.